Advances in Immune Thrombocytopenia: Expert Guidance to Navigate an Evolving Therapeutic Landscape

Join us for this CME live interactive symposium highlighting the advances in immune thrombocytopenia (ITP). Oncology experts Keith McCrae MD, Nichola Cooper, MD, and Rachael Grace, MD, MMSc, share their insights for the optimal management of ITP including discussion around patient cases, and the opportunity to get your questions answered by the experts.

Friday Satellite Symposium on Advances in Immune Thrombocytopenia: Expert Guidance to Navigate an Evolving Therapeutic Landscape, preceding the 63rd ASH Annual Meeting and Exposition.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


Welcome, Introduction, and Baseline Assessment

Real-World Cases and Panel Discussion

     Case Discussion 1: Initial Management of ITP: Diagnosis and Treatment Considerations – Dr. Cooper

     Case Discussion 2: Clinical Application of New Advances in the Management of Refractory ITP – Dr. McCrae

     Panel Discussion: Vaccines / Caring for Special Populations of Patients With ITP/Thrombocytopenia – Dr. Grace

Summary, Final Thoughts, Posteducation Assessment, and Audience Question and Answer


Date / Time
Event Details


Program Director
Keith R. McCrae, MD

Professor of Molecular Medicine
Department of Hematology and Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio, USA

Nichola Cooper, MD

Honorary Consultant Hematologist
Hammersmith Hospital
Imperial College
London, United Kingdom

Rachael Grace, MD, MMSc

Assistant Professor of Pediatrics
Harvard Medical School
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, Massachusetts, USA

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners in using new and emerging therapeutic options for patients with ITP.

Target Audience
This program is intended for physicians and other healthcare professionals who care for patients with ITP.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify newly diagnosed patients with ITP who would benefit from intensified therapy to improve remission rates
  • Select optimal second or subsequent lines of therapy for patients with ITP who have had an insufficient response to corticosteroids, immunoglobulins, splenectomy, and/or a thrombopoietin receptor agonist
  • Plan therapeutic strategies to manage thrombocytopenia in special populations of patients, including children, pregnant women, those with COVID-19, chronic liver disease, undergoing a planned medical procedure, or receiving chemotherapy
  • Evaluate new clinical trial data and the clinical practice implications of novel targeted therapies in patients with immune thrombocytopenia
  • Discuss ongoing clinical trials investigating novel targeted therapies and combination regimens for the treatment of immune thrombocytopenia


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.